A radioimmunoassay (RIA) for human pro-LRF(14-69)OH was developed with an antiserum, generated in a rabbit, to [Tyr67]pro-LRF(47-67)NH2 conjugated to BSA. This antiserum bound 28-32% of [125I]pro-LRF(14-69)0H at a final dilution of 1: 2500 and the binding was inhibited by pro-LRF(14-69)OH in a dose-dependent manner. The sensitivity of the RIA was 31.2-62.5 pg and the dose that inhibited 50% of the binding to the tracer was 280-320 pg.
Cloning and sequence analysis of the human luteinizing hormone-releasing factor (LRF) has revealed that the decapeptide LRF is synthetized in the form of a larger precursor of 69 amino acids (Seeburg and Adelman, 1984) . The mature LRF sequence lies in the amino terminal of this precursor and is connected to a 56-amino acid peptide by a processing and amidation sequence Gly-Lys-Arg. The 56-residue peptide ; pro-LRF(14-69)OH, that occupies the carboxyterminal region of pro-LRF has been shown to be a potent inhibitor of prolactin secretion as well as a stimulator for the release of gonadotropins in rat pituitary cell cultures (Nikolics et al., 1985) . In addition, the co-existence of pro-LRF(14-69)OH related antigen and LRF within rat hypothalmic tissue has been demonstrated by an immunocytochemical technique (Phillips et al., 1985) .
In an attempt to explore the physiological significance of pro-LRF(14-69)OH, we have generated an antiserum to a synthetic fragment of human pro-LRF,[Tyr67]pro-LRF (47-67)NH2. In this paper, we report the development of a radioimmunoassay for human pro-LRF(14-69)OH using this anti- (47-67)NH2 but was not affected by either pro-LRF(14-69)OH or human hypothalamic extract (Fig.1) . The highest specific activity of [125I]pro-LRF(14-69)OH prepared by the chloramine T method was only 30 of [1251_Tyr67]pro-LRF(47-67)NH2. The lack of a tyrosine residue in human pro-LRF (14-69)OH may account for this difference in radioiodine incorporation.
The antiserum bound 28-32% of [1251] pro-LRF(14-69)OH at a final dilution of 1: 2500. Fig.2 shows a standard curve for pro-LRF(14-69)OH RIA and a dilution curve of the human hypothalamic extract on the displacement of the tracer. Included in the figure is the crossreactivity of the antiserum with LRF, pro-LRF(1 4-37)OH, [Tyr67]pro-LRF(47-67) NH2. The displacement curves generated by increasing concentrations of the human hypothalamic extract and [Tyr67]pro-LRF (47-67)NH2 paralleled that of pro-LRF (14-69)OH. Neither LRF nor pro-LRF(14-37)OH was recognized by the antiserum. The sensitivity of the RIA was 32.1-62.5 pg and the dose that inhibited 50% of the binding to the tracer was 280-320 pg. Intra-and inter-assay coefficients of variation at 50% inhibition were 8 and 12%, respectively.
When human hypothalamic extract was subjected to gel chromatography on Sephadex G-50, a major immunoreactive peak emerged in elution volumes identical to that of [125I]pro-LRF(14-69)OH (Fig.3) .
Discussion
Human pro-LRF(14-69)OH has been proposed to be a prolactin release inhibiting factor (Nikolics et al., 1985) . Because of Even though rat pro-LRF(14-69)OH has 17 amino acid substitutions relative to human pro-LRF(14-69)OH (Adelman et al., 1986) , the present RIA revealed that rat hypothalamic tissue also contained materials which could displace the tracer in parallel to synthetic human pro-LRF(14-69)OH (data not shown). In addition this antiserum detected immunoreactive material(s) in LRFcontaining neurones of the rat brain as well as the co-existence of pro-LRF(14-69)OHlike peptides with LRF in secretory granules at the nerve endings in the median eminence (Ibata et al., in preparation) .
These results are in accord with those obtained by previous workers (Nikolics et al., 1985; Phillips et al., 1985) and suggest that rat pro-LRF (14-69)OH was also recognized by the antiserum.
However, our preliminary study showed that administration of the present antiserum to rats under several conditions did not augment plasma prolactin levels. The lack of response on prolactin may be due to the titer of the antiserum which was not high enough to neutralize the endogenous rat pro-LRF(14-69)OH, the proposed prolactin release-inhibiting factor (Adelman et al., 1986) . Further studies are required to examine the physiological significance of pro-LRF(14-69)OH on the regulation of prolactin and gonadotropin secretions.
